Abstract
Marlieke de Kraker and colleagues reflect on the need for better global estimates for the burden of antimicrobial resistance.
MeSH terms
-
Anti-Infective Agents / standards*
-
Drug Resistance, Microbial*
-
Humans
-
Mortality / trends*
Grants and funding
For MdK and SH, the research leading to this viewpoint has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreements nos. 115523, 115620, and 115737 (Combatting Bacterial Resistance in Europe projects [COMBACTE]), resources of which are composed of financial contribution from the European Union's 7th Framework Programme (FP7/2007–2013) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) companies’ in kind contribution. The funders had no role in data collection and analysis, decision to publish, or preparation of the manuscript.